NYSE:ALife Sciences
Agilent Technologies (A) Valuation Check After CRISPR Patent Loss And BioTek Cytation 9 Launch
Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek Cytation 9 cell imaging multimode reader.
See our latest analysis for Agilent Technologies.
At a share price of $120.39, investors have seen a 7.96% 1 month share price return and a 5.72% 7 day gain. However, the 90 day share price return of 17.50% and year to date share price return of 12.73%...